The regulatory mechanism of SLC25A11 in the metabolic remodeling of esophageal squamous cell carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068002

Enrollment

Unknown

Registered

2023-02-02

Start date

2023-02-03

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal squamous cell carcinoma

Interventions

Corresponding normal epithelial tissue of the esophagus adjacent to cancer:no

Pre-cancerous tissue of the esophagus:no

esophageal squamous cell carcinoma:no

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with esophageal squamous cell carcinoma: those presenting with retrosternal stagnation or dysphagia after eating, or asymptomatic patients with abnormal oesophageal masses on gastroscopy, with a post-surgical pathological diagnosis of squamous cell carcinoma of the esophagus. Corresponding normal epithelial tissue of the esophagus adjacent to cancer. Pre-cancerous tissue of the esophagus confirmed by pathology in post-operative specimens with squamous cell carcinoma.

Exclusion criteria

Exclusion criteria: Esophagitis, benign tumors of the esophagus, hiatal hernia, varices of the esophagus and other conditions causing similar symptoms to esophageal squamous cell carcinoma.

Design outcomes

Primary

Measure	Time frame
Expression level of SLC25A11;	—

Countries

China

Contacts

Public ContactWeiqing Chen

Chongqing University Cancer Hospital

2687836314@qq.com+86 139 8369 5334

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026